Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder

The optimal treatment for schizoaffective disorder (SCA) is not well established. In this initial 6-month open-label treatment period of a large, multiphase, relapse-prevention study, the efficacy and safety of paliperidone palmitate once-monthly (PP1M) injectable were evaluated in subjects with sym...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Dong-Jing, Turkoz, Ibrahim, Simonson, R. Bruce, Walling, David, Schooler, Nina, Lindenmayer, Jean-Pierre, Canuso, Carla, Alphs, Larry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932150/
https://www.ncbi.nlm.nih.gov/pubmed/27322760
http://dx.doi.org/10.1097/JCP.0000000000000535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932150/
https://www.ncbi.nlm.nih.gov/pubmed/27322760
http://dx.doi.org/10.1097/JCP.0000000000000535

Ejemplares similares